Table 2.
Descriptive summary table of selected studies (n = 27)
| Author | Country | MSA† Tested | Study sample (n) | Mean age (year) | Type of IIM studied | Diagnostic approach/diagnostic criteria used | Mean delay (months) | Mean delay SD⁂ (months) |
|---|---|---|---|---|---|---|---|---|
| Retrospective cohort studies | ||||||||
| Baccaro et al. [26] | Brazil | Yes | 55 | Not reported | ASS | Criteria proposed by Connors et al. and Cavagna et al. [51, 52] | 29 | 8.99 |
| Cobo-Ibanez et al. [25] | Spain | Yes | 478 | 47.7 | All types of IIM | Peter and Bohan’s criteria | 3.48 | 7.85 |
| Triplett et al. [41] | United States | Yes | 67 | Not reported | NM | Biopsy and electromyography | 8.5 | 28.04 |
| Time series with comparison group | ||||||||
| Sayers et al. [21] | United States | No | 32 | 61 | IBM | Peter and Bohan’s criteria | 34 | 24.7 |
| Analytical cross-sectional studies or time series | ||||||||
| Cavagna et al. [18] | Multi-national | Yes | 44 | 53.5 | ASS | Clinical characteristics and positive anti Jo-1 | 5 | 6.51 |
| Kazamel et al. [24] | United States | No | 51 | Not reported | IBM | Grigg's pathological criteria [53] | 74.4 | 75.67 |
| Mathiesen et al. [15] | Denmark | No | 57 | Not reported | JDM | Peter and Bohan’s criteria | 8 | 1.6 |
| Pijnenburg et al. [37] | France | No | 40 | 48.2 | All types of IIM | ENMC criteria | 16.4 | 4.5 |
| Wargula et al. [20] | United States | No | 59 | 7.9 | JDM | Peter and Bohan’s criteria | 5.3 | 5.2 |
| Williams et al. [19] | Australia | No | 13 | 68 | All types of IIM | Serum creatinine kinase level, electromyography, and biopsy | 55 | 53.49 |
| Non-comparative studies (descriptive cross-sectional studies, survey and prevalence or incidence studies) | ||||||||
| Badrising et al. [16] | The Netherlands | No | 76 | Not reported | IBM | ENMC criteria of 1997 | 96 | 71.24 |
| Da Silva et al. [29] | United States | No | 232 | Not reported | DM | Not reported | 15.5 | 46.61 |
| Dobloug et al. [9] | Norway | Yes | 100 | Not reported | IBM | ENMC criteria of 1997 or 2011 | 67.2 | 60 |
| Felice et al. [17] | United States | No | 35 | 70 | IBM | Definite or possible IBM as proposed by Griggs et al. [53] | 68.4 | 68.47 |
| Lynn et al. [14] | New Zealand | No | 6 | Not reported | IBM | Peter and Bohan’s criteria/Mastaglia and Phillips [54] | 43.2 | 10.3 |
| Needham et al. [23] | Australia | No | 57 | Not reported | IBM | Needham and Mastaglia’s criteria [55] | 62.4 | 39.24 |
| Paltiel et al. [36] | Multi-national | No | 280 | 70.4 | IBM | Not reported | 56.4 | Not reported |
| Phillips et al. [22] | Australia | No | 17 | Not reported | IBM | Grigg's pathological criteria [53] | 52.8 | 26.72 |
| Rotar et al. [38] | Slovenia | No | 79 | Not reported | All types of IIM | Records of biopsy | 6.66 | 6.77 |
| Non-comparative studies (Case reports) | ||||||||
| De Langhe et al. [31] | Belgium | Yes | 1 | 44 | ASS | Clinical characteristics and presence of antisynthetase antibodies | 48 | Not calculatable |
| Devi et al. [32] | India | Yes | 1 | 35 | ASS | Not reported | 0 | Not calculatable |
| Dickison et al. [33] | United States | Yes | 1 | 31 | DM | Clinical characteristics and biopsy | 120 | Not calculatable |
| Herath et al. [28] | Sri Lanka | Yes | 1 | 53 | DM | Peter and Bohan’s criteria | 5 | Not calculatable |
| Hom et al. [34] | United States | No | 1 | 58 | IBM | Biopsy | 60 | Not calculatable |
| Kucuksen et al. [27] | Turkey | No | 1 | 63 | IBM | Biopsy | 60 | Not calculatable |
| Munshi et al. [35] | UK | No | 1 | 81 | IBM | Biopsy | 36 | Not calculatable |
| Non comparative studies (Case series) | ||||||||
| Chilingaryan et al. [30] | United States | No | 20 | 67.8 | IBM | Not reported | 70 | 54.8 |
†MSA- myositis specific antibody test
⁂SD- Standard deviation